Stepping Forward to Transform Mantle Cell Lymphoma (MCL) Management: Guidance on the Selection and Use of BTK Inhibitors (BTKi)

Faculty Affiliations and Disclosures

**Chair and Moderator**
Pier Luigi Zinzani, MD, PhD
Institute of Hematology
“Seragnoli”
University of Bologna
Bologna, Italy

Pier Luigi Zinzani, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; BeiGene; Bristol Myers Squibb; Incyte; Janssen; Kite, a Gilead Company; Kyowa Kirin; Lilly; Merck; Novartis; Recordati; Regeneron; Roche; SOBI; Takeda Speaker for AbbVie; BeiGene; Bristol Myers Squibb; Incyte; Janssen; Kite, a Gilead Company; Kyowa Kirin; Lilly; Merck; Novartis; Recordati; Regeneron; Roche; SOBI; Takeda

**Faculty and Presenter**
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Hematology Consultant
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio, Inc.
Grant/Research Support from AstraZeneca and BeiGene.
Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; and Loxo Oncology, Inc.

**Faculty and Presenter**
Christine Ryan, MD
Instructor in Medicine, Harvard Medical School
Leader, Mantle Cell Lymphoma, Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts, US

Disclosure is pending.